Osteoporosis.  2012 Dec;10(3):112-118.

The Relationship between Wnt Antagonist Genes Polymorphisms and Changes in Production of Osteoprotegerin and Soluble Receptor Activator of NF-kB by Whole Blood Cells after Hormone Therapy

Affiliations
  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. kimjg@snu.ac.kr
  • 2Department of Obstetrics and Gynecology, National Cancer Center, Goyang, Korea.
  • 3Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.

Abstract


OBJECTIVES
To investigate the relationship between single nucleotide polymorphism (SNP)s in Wnt antagonist genes, and production of osteoprotegerin (OPG) and soluble receptor activator of NF-kappaB ligand (sRANKL) by whole blood cells after hormone therapy (HT) in postmenopausal Korean women.
MATERIALS AND METHODS
The Dkk1 c.318A>G, Dkk2 c.437G>A, Dkk3 c.1003A>G polymorphisms and sFRP3 c.970C>G, sFRP4 c.958C>A, and c.1019G>A polymorphisms, and sFRP5 c.20G>C polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, and Taqman assay in 75 postmenopausal Korean women receiving estrogen-progestogen therapy. The production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells (WBC) before and after HT of 6 months were also measured.
RESULTS
Changes in the production of OPG and sRANKL by lipopolysaccharide-stimulated WBC, and in ratios of sRANKL(x1,000)/OPG after HT of 6 months were not different according to SNPs in Wnt signal pathway genes except Dkk1 c.318A>G SNP. The AA genotype of Dkk1 c.318A>G SNP showed significantly higher changes (p<0.05) in ratios of sRANKL(x1,000)/OPG compared to other genotypes. There were no significant differences in changes in the production of OPG and sRANKL, and in ratios of sRANKL(x1,000)/OPG among combined genotypes of sFRP4 c.958C>A, and c.1019G>A polymorphisms after HT.
CONCLUSIONS
Dkk1 c.318A>G SNP are related with changes in ratios of sRANKL(x1,000)/OPG in terms of the production of OPG and sRANKL by lipopolysaccharide-stimulated whole blood cells after HT.

Keyword

Hormone therapy; Osteoprotegerin; Receptor activator of nuclear factor-kB ligand; Whole blood cell; Wnt antagonist polymorphism

MeSH Terms

Blood Cells
Female
Genotype
Humans
NF-kappa B
Osteoprotegerin
Polymorphism, Single Nucleotide
Receptor Activator of Nuclear Factor-kappa B
Signal Transduction
NF-kappa B
Osteoprotegerin
Receptor Activator of Nuclear Factor-kappa B
Full Text Links
  • OST
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr